

Status Of CREST-2 What Will It Tell Us And When





Primary Aims




In patients with ≥70% asymptomatic stenosis, to assess:

- The treatment differences between medical management and CEA
- The treatment differences between medical management and CAS

Primary endpoint: any stroke or death within 44 days of randomization or ipsilateral ischemic stroke thereafter up to 4 years


Two Concurrent Two-arm Trials



Lal BK, Meschia J, Brott TG et al. Semin Vasc Surg 2017 Howard V, Meschia J, Lal BK et al. Int J of Stroke 2017

CREST-2 Enrolling Centers

CREST-2 Core Centers





Medical Management

- CEA Trial: aspirin 325mg/d
- CAS Trial: dual antiplatelet therapy for ≥1 month post-procedure; then aspirin
- Both Trials: statin (PCSK9 inhibitors as needed)

Primary Risk Factor Targets

- Systolic BP <130 mm Hg
- LDL cholesterol <70 mg/dl

Secondary Risk Factor Targets

- Non-HDL cholesterol <100 mg/dl
- Hemoglobin A1c <7.0%
- Smoking cessation
- Targeted weight management
- >30 minutes of moderate exercise 3 times a week

Medical Management



Percentage of CREST-2 enrolled patients in-target for each risk factor


Risk Factor	Baseline	<u>1 Month</u>	<u>4 Month</u>	Last Follow UP
SBP	63%	71%	79%	85%
LDL	43%	57%	69%	67%
Non HDL	47%	60%	67%	68%
HgA1C1	47%	47%	47%	49%
Smoking	79%	80%	81%	80%
Physical Activity	50%	54%	62%	60%
Weight	23%	25%	27%	29%

As of October 8, 2018



Projected vs. Actual Enrollment


Cumulative Randomizations





Enrollment

- CEA was lagging behind the CAS trial
- Not so any more!



As of October 5, 2018

Increasing Diversity

Women and Minorities Committee Activities

- Administered and analyzed survey of 90+ CREST-2 coordinators
- Piloted a 'Lunch and Learn' program in Huntsville, LA to engage primary care physicians in CREST- 2 screening
 - Generated 7 referrals of African American patients in under 2 months
- Enhanced recruitment and retention resources on CREST-2 website 'Women and Minorities' tab
- Creating additional recruitment videos and scripts for PIs and coordinators
- Contracted with Life Line screening to increase referrals to CREST-2
- Meeting with individual sites to troubleshoot barriers and promote best practices
- Hosting 2 upcoming webinars







Objectives

- Rapid initiation and completion of enrollment in CREST-2 by credentialing high-quality operators
- CAS is performed safely by adequately experienced operators

Symptomatic	44.1%
Asymptomatic- Primary atherosclerosis	38.2%
Asymptomatic- Restenosis	17.7%
30-day stroke and death	2.51%
Access site complications	3.4%
Dysrhythmia	0.7%







StrokeNet Randomizations

2018 CREST-2 Randomizations 60 50 StrokeNet 40 Non-StrokeNet 30 20 10 0 Jan Feb Mar Apr May Jun Jul Aug Sept

<u>Please pull out the stops to uptick CREST-2 enrollment</u>. **If** the StrokeNet sites can match the Non-StrokeNet sites, CREST-2 will be on track to meet NINDS expectations.



CREST-2/H NEEDS YOU



